GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicine Man Technologies Inc (OTCPK:SHWZ) » Definitions » Debt-to-EBITDA

Medicine Man Technologies (Medicine Man Technologies) Debt-to-EBITDA : -4.16 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Medicine Man Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicine Man Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $8.5 Mil. Medicine Man Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $183.4 Mil. Medicine Man Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-46.1 Mil. Medicine Man Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -4.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medicine Man Technologies's Debt-to-EBITDA or its related term are showing as below:

SHWZ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.09   Med: -0.01   Max: 5.02
Current: 5.02

During the past 10 years, the highest Debt-to-EBITDA Ratio of Medicine Man Technologies was 5.02. The lowest was -1.09. And the median was -0.01.

SHWZ's Debt-to-EBITDA is ranked worse than
80.97% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs SHWZ: 5.02

Medicine Man Technologies Debt-to-EBITDA Historical Data

The historical data trend for Medicine Man Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicine Man Technologies Debt-to-EBITDA Chart

Medicine Man Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -1.09 3.08 3.98 5.02

Medicine Man Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 1.90 4.09 2.50 -4.16

Competitive Comparison of Medicine Man Technologies's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Medicine Man Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicine Man Technologies's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicine Man Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medicine Man Technologies's Debt-to-EBITDA falls into.



Medicine Man Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medicine Man Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.47 + 183.396) / 38.194
=5.02

Medicine Man Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.47 + 183.396) / -46.112
=-4.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Medicine Man Technologies  (OTCPK:SHWZ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medicine Man Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medicine Man Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicine Man Technologies (Medicine Man Technologies) Business Description

Traded in Other Exchanges
Address
4880 Havana Street, Suite 201, Denver, CO, USA, 80239
Medicine Man Technologies Inc is engaged in providing general consulting services in the cannabis industry. The company also provide seminar which includes giving guidance and tips on industry opportunities, medical and recreational market trends, cultivation methodologies and technology, extraction technology, dispensary operation, security requirements. The company's operating segment includes- Retail, consisting of retail locations for sale of cannabis products; Wholesale, consisting of manufacturing, cultivation and sale of both wholesale cannabis and non-cannabis products; Other, consisting of all other income and expenses. It generates maximum revenue from the Retail segment. The company is now operating under its new trade name, Schwazze.
Executives
Christine Jones officer: Chief Legal Officer C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Forrest Hoffmaster officer: CFO C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Nirup Krishnamurthy director, officer: President 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Kathy P Vrabeck director 625 WESTPORT PARKWAY, GRAPEVINE TX 76051
Jeff Garwood director 55 TABBY CIRCLE, DAUFUSKIE ISLAND SC 29915
Pratap Chandra Mukharji director 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Salim Husan Wahdan director 4880 HAVANA ST., STE. 201, DENVER CO 80239
Paul Joseph Montalbano director 4880 HAVANA ST., STE. 201, DENVER CO 80239
Brad Stewart director C/O SEMPER PARATUS ACQUISITION CORP., 767 THIRD AVENUE, 38TH FLOOR, NEW YORK NY 10017
Justin Dye director, 10 percent owner, officer: CEO C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA STREET, SUITE 201, DENVER CO 80239
Jeffrey Alley Cozad director, 10 percent owner C/O MEDICINE MAN TECHNOLOGIES, INC., 4880 HAVANA ST., SUITE 201, DENVER CO 80239
Crw Capital Holdings Ii, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, STE 195579, DALLAS TX 75209
Crw Capital, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, P.O. BOX 195579, DALLAS TX 75209
Crw Capital Cann Holdings, Llc 10 percent owner 4740 W. MOCKINGBIRD LANE, P.O. BOX 195579, DALLAS TX 75209
Brian Ruden 10 percent owner C/O 4880 HAVANA STREET, SUITE 102, DENVER CO 80239